Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma
Martine Cohen‐Solal(Université Paris Cité), M.C. de Vernejoul(Inserm), A. Valentin-Opran(Unknown), B Amor(Hôpital Cochin), Maxime Dougados(Délégation Paris 5), Christian Roux(Hôpital Cochin)
Cited by 14
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
|New England Journal of Medicine|2005|1.2k
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
|Annals of the Rheumatic Diseases|2006|798
Recombinant Human BMP-2 and Allograft Compared with Autogenous Bone Graft for Reconstruction of Diaphyseal Tibial Fractures with Cortical Defects
|Journal of Bone and Joint Surgery|2006|447